Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.05 (-5.24%)
Close on Nov 13, 2026Market cap $280.72MP/E –Yield –
Ocugen cash
Cash and short-term investments held at the end of each period.
Ocugen's cash was $84.30M at Sep 30, 2026. For fiscal 2025 it was $18.57M, down 68.4% from the year before. Over ten years it grew -5.0% a year on average. The highest annual figure on record is $95.11M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.57M | -68.4% |
| FY2024 | Dec 31, 2024 | $58.82M | +49.1% |
| FY2023 | Dec 31, 2023 | $39.46M | -56.6% |
| FY2022 | Dec 31, 2022 | $90.93M | -4.4% |
| FY2021 | Dec 31, 2021 | $95.11M | +293.2% |
| FY2020 | Dec 31, 2020 | $24.19M | +218.5% |
| FY2019 | Dec 31, 2019 | $7.60M | +326.9% |
| FY2018 | Dec 31, 2018 | $1.78M | -75.3% |
| FY2017 | Dec 31, 2017 | $7.20M | -77.5% |
| FY2016 | Dec 31, 2016 | $32.05M | +3.7% |
| FY2015 | Dec 31, 2015 | $30.92M | -47.2% |
| FY2014 | Dec 31, 2014 | $58.53M | +570.1% |
| FY2013 | Dec 31, 2013 | $8.73M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $84.30M | +158.9% |
| Q2 FY2026 | Jun 30, 2026 | $100.05M | +270.4% |
| Q1 FY2026 | Mar 31, 2026 | $31.90M | -15.6% |
| Q4 FY2025 | Dec 31, 2025 | $18.57M | -68.4% |
| Q3 FY2025 | Sep 30, 2025 | $32.57M | -15.8% |
| Q2 FY2025 | Jun 30, 2025 | $27.01M | +72.1% |
| Q1 FY2025 | Mar 31, 2025 | $37.80M | +43.3% |
| Q4 FY2024 | Dec 31, 2024 | $58.82M | +49.1% |
| Q3 FY2024 | Sep 30, 2024 | $38.70M | -27.6% |
| Q2 FY2024 | Jun 30, 2024 | $15.70M | -77.8% |
| Q1 FY2024 | Mar 31, 2024 | $26.38M | -65.6% |
| Q4 FY2023 | Dec 31, 2023 | $39.46M | -56.6% |
| Q3 FY2023 | Sep 30, 2023 | $53.48M | -47.4% |
| Q2 FY2023 | Jun 30, 2023 | $70.58M | -38.6% |
| Q1 FY2023 | Mar 31, 2023 | $76.72M | -40.9% |
| Q4 FY2022 | Dec 31, 2022 | $90.93M | -4.4% |
| Q3 FY2022 | Sep 30, 2022 | $101.60M | -5.4% |
| Q2 FY2022 | Jun 30, 2022 | $115.01M | -0.6% |
| Q1 FY2022 | Mar 31, 2022 | $129.77M | +189.7% |
| Q4 FY2021 | Dec 31, 2021 | $95.11M | +293.2% |
| Q3 FY2021 | Sep 30, 2021 | $107.35M | +461.9% |
| Q2 FY2021 | Jun 30, 2021 | $115.64M | +672.6% |
| Q1 FY2021 | Mar 31, 2021 | $44.79M | +1302.8% |
| Q4 FY2020 | Dec 31, 2020 | $24.19M | +218.5% |
| Q3 FY2020 | Sep 30, 2020 | $19.11M | +24.9% |
| Q2 FY2020 | Jun 30, 2020 | $14.97M | +2106.1% |
| Q1 FY2020 | Mar 31, 2020 | $3.19M | +934.3% |
| Q4 FY2019 | Dec 31, 2019 | $7.60M | +326.9% |
| Q3 FY2019 | Sep 30, 2019 | $15.30M | +516.0% |
| Q2 FY2019 | Jun 30, 2019 | $678.49K | -92.3% |
| Q1 FY2019 | Mar 31, 2019 | $308.72K | -98.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.78M | -75.3% |
| Q3 FY2018 | Sep 30, 2018 | $2.48M | -80.3% |
| Q2 FY2018 | Jun 30, 2018 | $8.77M | -52.6% |
| Q1 FY2018 | Mar 31, 2018 | $15.51M | -36.4% |
| Q4 FY2017 | Dec 31, 2017 | $7.20M | -77.5% |
| Q3 FY2017 | Sep 30, 2017 | $12.60M | – |
| Q2 FY2017 | Jun 30, 2017 | $18.50M | – |
| Q1 FY2017 | Mar 31, 2017 | $24.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $32.05M | – |
See a number that looks wrong?